On December 27 last year, Pfizer had moved to the US District Court for the District of Delaware against Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories Inc for infringement of Pfizer's crystalline atorvastatin patent.
The company had stopped production of generic version of cholesterol lowering drug Lipitor last year as it investigated the issue of potential glass particles in certain lots of the drug.
India's largest drug maker Ranbaxy Laboratories, which is fighting a patent battle with the world's largest drug maker Pfizer on the cholesterol lowering drug Lipitor in about 18 countries, got a mixed verdict from the Full Court of Federal Court of Australia.
In its ongoing patent litigation over cholesterol lowering drug atorvastatin (Lipitor) against India's Ranbaxy Laboratories, Pfizer said on Tuesday in a court in Ireland had ruled in its favour.
In a boost to Ranbaxy in its ongoing litigation over anti-cholesterol drug Lipitor (atorvastatin) against Pfizer, a Norway court today ruled that four of the US pharma giant's patents were either invalid or not infringed by the Indian company.
A US court has ruled against Ranbaxy in its case for non-infringement and invalidation of two patents of its competitor Pfizer
The drug had generated sales of $600 million in the first six months of its launch in the US, as Ranbaxy had exclusive marketing rights for it.
Less than three months after roaring into us market with generic for cholesterol-reducing Lipitor, Dept of Justice files for permanent injunction against Ranbaxy.
The firm, however, said the anti-cholesterol tablets meant for the US market will be produced at its Mohali SEZ plant in Punjab and not at the three units banned by the US health regulator.
Pfizer has won a patent challenge in Denmark by India's largest drug-maker Ranbaxy Laboratories on atorvastatin, the active ingredient of the world's largest selling cholesterol drug, Lipitor, which has global sales of over $13 billion.
Shares of Ranbaxy Laboratories on Thursday fell 7.67 per cent on the Bombay Stock Exchange to Rs 552.25 at close, after top investment banks like JP Morgan and CLSA said the out-of-court settlement with Pfizer over cholesterol pill Lipitor announced on Wednesday would delay the launch of the drug in the US by well over a year.
India's largest drug maker Ranbaxy was at the receiving end of two patent infringement cases in Denmark and the USA on February 23
Country's biggest drug maker, Ranbaxy Laboratories Ltd on Wednesday said a US Appeals Court has ruled in its favour in the patent infringement case with Pfizer for cholesterol-lowering drug Atorvastatin (Lipitor).
Leading Indian drug firm Ranbaxy has launched court battles in Britain and the US against the American pharmaceutical giant Pfizer for the rights to produce the cholesterol drug atorvastatin at a cheaper price.
Get rid of these bad habits, says Upendra Kaul.
The callousness with which these political dissidents are being treated goes against the Supreme Court's directive, given right at the beginning of the lockdown. The apex court had directed states to release prisoners to decongest jails, which had become hotspots of the coronavirus.
The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States.
The Sensex closed down 308 points at 24,894 and the Nifty has lost 96 points at 7,559.
Medicines, including antibiotics, contraceptives and anti-diabetic drugs, were found to be out of stock at various places around Delhi.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances